LYTACs
Lysosome-targeting chimeras
Lysosome targeting chimera (LYTAC) degrades target proteins via lysosomal pathway rather than common proteasome pathway. LYTAC degrades target proteins by binding to asialoglycoprotein receptor on lysosomal through its asialoglycoprotein receptor ligand. Another side of LYTAC is usually an antibody so it can bind to target protein for degradation.
All Product Categories
-
LYTACs Related Products (24)
Related Products (24)
-
Antibodies (1)
- 1
- 2
-
Atz-L5
0 ImagesCat. No.: HY-181830Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC50: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1 in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer.
-
dPDL1-4
0 ImagesCat. No.: HY-174468dPDL1-4 is a potent and selective eHSPTAC eHSP90 PD-L1 degrader with DC50s of 7.77 μM and 6.52 μM in HeLa and B16F10 cells. dPDL1-4 bridges eHSP90 with the target protein, inducing lysosomal degradation. dPDL1-4 can degrade PD-L1 significantly and inhibits tumor growth. dPDL1-4 can be used for the study of cervical cancer and melanoma. ((Pink: eHSP90 ligand (HY-174476); Blue: PD-L1 ligand (HY-116274); Black: Linker (HY-W021787); HSP ligand + linker: HY-174799)).
-
GalNac-L96 analog
0 ImagesCat. No.: HY-153527CAS No.: 1159408-72-6GalNAc-L96 analog is an intermediate in the synthesis of the asialoglycoprotein receptor (ASGPR) ligand GalNAc-L96 (HY-147012).
-
tri-GalNAc-COOH (acetylation)
0 ImagesCat. No.: HY-145013CAS No.: 3008204-26-7tri-GalNAc-COOH acetylation is the acetylated and modified form of tri-GalNAc-COOH. tri-GalNAc-COOH acetylation can be used for the synthesis of LYTAC.
- 1
- 2
